Fiera Capital Corp Boosts Stock Position in Biohaven Ltd. $BHVN

Fiera Capital Corp grew its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 724,551 shares of the company’s stock after acquiring an additional 163,197 shares during the period. Fiera Capital Corp’s holdings in Biohaven were worth $8,180,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BHVN. AQR Capital Management LLC raised its position in shares of Biohaven by 49.4% in the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after buying an additional 37,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Biohaven by 32.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after buying an additional 17,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Biohaven by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock worth $14,174,000 after buying an additional 41,040 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Biohaven by 80.3% in the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock worth $1,481,000 after buying an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP raised its position in shares of Biohaven by 1,097.8% in the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after buying an additional 8,102 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Morgan Stanley reduced their target price on Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. Citigroup increased their target price on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Royal Bank Of Canada reduced their target price on Biohaven from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Stock Down 0.1%

BHVN opened at $11.11 on Wednesday. The company has a market cap of $1.67 billion, a P/E ratio of -1.96 and a beta of 1.35. The business’s 50-day moving average price is $9.84 and its 200-day moving average price is $10.47. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. Biohaven Ltd. has a 12 month low of $7.48 and a 12 month high of $18.57.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, equities analysts expect that Biohaven Ltd. will post -3.07 EPS for the current year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.